Brief Summary

This is an expanded access designed to provide access to apixaban for eligible participants.

Individual Patients

Drug: Apixaban
Administered as directed by treating physician
Other Name: Eliquis

Eligibility Criteria

Inclusion Criteria: - Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention - Previously participated in the CV185-362 study and was on apixaban for 1 year or until treatment was no longer required

Exclusion Criteria: - Weight less than 5 kg or greater than 35 kg

Other inclusion/exclusion criteria apply

Eligibility Gender
Eligibility Age
Minimum: 28 Days~Maximum: 17 Years
United States

Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104


Investigator: Andrew Glatz, Site 0001


Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:

First line of the email MUST contain NCT # and Site #.

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

Bristol-Myers Squibb
NCT Number
MeSH Terms